Table 2.
Findings at last follow-up in the treatment groups, values as median (IQR) where not otherwise specified
| Groups | ||||||
|---|---|---|---|---|---|---|
| Variables | Conservative (Con) n = 121 | Pacing n = 88 | Myectomy (Mye) n = 42 |
P-value |
||
| Con vs pacing | Con vs mye | Pacing vs mye | ||||
| Age at intervention (years) | ||||||
| Median (IQR) | 64 (22) | 43 (41) | <0.001 | |||
| Post-intervention FU (years) | ||||||
| Mean ± SD | 12.2 ± 5.0 | 12.9 ± 8.7 | ||||
| Median (IQR) | 11.8 (9.1) | 10.5 (12.4) | 0.81 | |||
| Cardiac mortality. n (%) | 25/121 (21) | 25/88 (28) | 15/42 (36) | 0.51 L-R | 0.31L-R | 0.45L-R |
| Annual cardiac mortality from diagnosis (%) | 1.8 | 1.7 | 1.9 | |||
| Annual sudden death mortality from diagnosis (%) | 0.44 | 0.21 | 0.63 | |||
| Annual cardiac mortality post-procedure (%) | 2.4 | 2.8 | ||||
| NYHA class | ||||||
| Mean ± SD | 1.9 ± 0.81a | 1.7 ± 0.7b | 1.8 ± 0.6a | |||
| Median (IQR) | 2 (1) | 2 (1) | 2 (1) | 0.21 | 0.70 | 0.43 |
| Beta-blocker use (%)c | 88 | 85 | 83 | 1.0 | 0.62 | 0.79 |
| Metoprolol dose (mg/day)d | 200 (150) | 150 (100) | 100 (150)e | 0.053 | 0.037 | 0.280 |
| Verapamil/diltiazem use (%)c | 12 | 17 | 5 | 0.342 | 0.161 | 0.057 |
| Disopyramide use (%)c | 12 | 7 | 24 | 0.192 | 0.163 | 0.016 |
| ICD implantations, n (%) | 5 (4) | 5 (6) | 7 (17) | 0.601 | 0.009 | 0.048 |
| LVOT gradient (mmHg)f | 23 (42)b | 14 (32)b | 11 (16)b | 0.013 | 0.003 | 0.381 |
| LVOT gradient >50 mmHg (%) | 24 | 17 | 14 | 0.23 | 0.19 | 0.92 |
| Septum (mm) | 20 (5) | 18 (5)a | 16 (7) | 0.17 | 0.002 | 0.013 |
| Posterior LV wall (mm) | 13 (5) | 13 (5) | 11 (4)a | 0.67 | 0.002 | 0.004 |
| LVEDD (mm) | 43 (7) | 45 (9) | 45 (11)a | 0.011 | 0.019 | 0.60 |
| LAD (mm) | 47 (10)b | 51 (14)b | 49 (15)e | 0.011 | 0.954 | 0.124 |
| LVEF (%) | 65 (10) | 63 (12)e | 60 (18)b | 0.36 | 0.12 | 0.41 |
Values are represented as median (IQR) where not otherwise specified.
Con, Conservative, medical therapy only; FU, follow-up; ICD, implantable cardioverter defibrillator; IQR, interquartile range; L-R, log-rank test of Kaplan–Meier analysis; LAD, left atrium diameter; LVEF, left ventricular ejection fraction; LVEDD, left ventricle end-diastolic diameter; LVOT, left ventricular outflow tract; Mye, myectomy; NYHA, New York Heart Association Class; PM, pacemaker; SD, standard deviation. Mann Whitney U test was used for inter-group comparisons unless otherwise specified. P-values in bold indicate significance.
Significant on paired test vs. pre-treatment values: P ≤ 0.01–0.002.
Significant on paired test vs. pre-treatment values: P ≤ 0.001. Mann–Whitney U test was used for inter-group comparisons unless otherwise specified.
χ2 test.
Metoprolol was the most common beta-blocker used, and thus doses of other beta-blockers have been converted to metoprolol equivalents.
Significant on paired test vs. pre-treatment values: P < 0.05–0.02.
Final result after any re-intervention.